<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02024217</url>
  </required_header>
  <id_info>
    <org_study_id>LAGCCS001</org_study_id>
    <nct_id>NCT02024217</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma</brief_title>
  <acronym>NEWEAR</acronym>
  <official_title>Phase II Study of Neoadjuvant Chemotherapy Wtih S1+Oxaliplatin (SOX) Regimen Followed by Chemoradiation Concurrent With S-1 in Patients With Potentially Resectable Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the feasibility, safety and tolerability of Preoperative Chemoradiation in
      Patients With Localized Gastric Cancer. Primary endpoint: R0 resection rate. Secondary
      endpoint: resection rate, pathological complete regression (pCR), effectiveness and safety of
      regime, disease free survival(DFS) and overall survival(OS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis of gastric cancer is poor partially due to low R0 resection rate. Neoadjuvant
      chemoradiotherapy was reported to be effective in this setting by several phase II studies.
      The investigators aim to evaluate the efficacy and toxicity of neoadjuvant chemoradiotherapy
      in a prospective phase II study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>6-8 Weeks</time_frame>
    <description>6-8 weeks after Radiation therapy，we evaluate the lesion，if it is resectable，we will give surgical therapy，</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of the treatment regimen</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>after neoadjuvant chemotherapy and chemoradiotherapy，we evaluate the side effects , and record the side effects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>resection rate</measure>
    <time_frame>6-8 Weeks</time_frame>
    <description>6-8 weeks after Radiation therapy，we evaluate the lesion，if it is resectable，we will give surgical therapy，</description>
  </other_outcome>
  <other_outcome>
    <measure>disease-free survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>after surgical therapy，we followup the patients and stat the recurrence and death and calculate the disease-free survival</description>
  </other_outcome>
  <other_outcome>
    <measure>over-all survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>after surgical therapy，we followup the patients and stat the recurrence and death and calculate the over-all survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>chemoradiotherapy, S1, oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemoradiotherapy is given before surgical therapy,S1(Tegafur，Gimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>S1，oxaliplatin，radiation</intervention_name>
    <description>Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;</description>
    <arm_group_label>chemoradiotherapy, S1, oxaliplatin</arm_group_label>
    <other_name>S1(Tegafur，Gimeracil and Oteracil Potassium Capsules)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18 ≤ age ≤ 70, Male or Female; 2.Minimum life expectancy of 6 months; 3.Patients with
        localized, histologically confirmed gastric or gastroesophageal adenocarcinoma; 4.Patients
        must have a performance status of &lt; 2 Eastern Cooperative Oncology Group (ECOG); 5.No prior
        major surgery of the stomach or radiation therapy to the stomach or immunotherapy or
        chemotherapy; 6.CT or MRI, endorectal ultrasonography (EUS), laparoscopic exploration are
        required to stage; 7.Without other benign diseases such as lung, kidney, liver infections;
        8.Without participating other clinical trials; 9.Patient must sign an informed consent
        prior to study entry; 10.Patients must have adequate bone marrow function (defined as
        peripheral absolute granulocyte count of &gt;1,500/µL, and platelet count of &gt; 100,000/µL),
        adequate liver function (bilirubin &lt;= 1.5 mg/dl), and adequate renal function (creatinine
        &lt;= 1.5 mg/dl). 11)Patients without cardiac disease , severe uncontrolled diabetes,
        hypertension, cerebrovascular disease, or infection.

        Exclusion Criteria:

          1. Pregnant women are excluded from study entry due to the potential teratogenic effects
             of the study treatment;

          2. Female patients who planed to have a baby;

          3. Prior radiation therapy to the stomach, liver or kidney;

          4. Dysfunction of important organs such as liver, kidney or heart; 5.Abnormalities of
             mental status;

        6.Active coronary artery disease; 7.Cardiac arrhythmia, and need to receive medication
        therapy; 8.Severe uncontrolled hypertension; 9.Active clinical serious infection; 10.The
        known human immunodeficiency virus (HIV) infection history; 11.The known central nervous
        system diseases, including brain metastatic tumors; 12.Patients have had clinical clear
        gastrointestinal bleeding in 6 months; 13.Drug abuse; 14.Swallowing difficulties for drugs;
        15.Poor compliance; 16.Presence of concurrent or previous malignancies (except for cervical
        carcinoma in situ or basal cell carcinoma of the skin); 17.Presence of peritoneal
        metastasis, distant organs or lymph nodes metastasis; 18.Presence history of major surgery
        in the past three months; 19.Poor tolerability; 20.Prior history of medication; 21.allergy
        for chemotherapeutic drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guichao Li, MD</last_name>
    <phone>862164175590</phone>
    <phone_ext>1606</phone_ext>
    <email>11111230012@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaowen Liu, MD</last_name>
    <email>liuxw1129@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guichao Li, MD</last_name>
      <email>11111230012@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiaowen Liu, MD</last_name>
      <email>liuxw1129@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhen Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009 Feb 20;27(6):851-6. doi: 10.1200/JCO.2008.17.0506. Epub 2009 Jan 12.</citation>
    <PMID>19139439</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>December 25, 2013</last_update_submitted>
  <last_update_submitted_qc>December 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhen Zhang</investigator_full_name>
    <investigator_title>Chairman of Department of Radiation Oncology Fudan University Shanghai Cancer Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

